Basic Study
Copyright ©The Author(s) 2025.
World J Gastroenterol. Apr 14, 2025; 31(14): 104975
Published online Apr 14, 2025. doi: 10.3748/wjg.v31.i14.104975
Table 1 Clinical features of five patients and the corresponding ATP-binding cassette subfamily B member 4 mutations
No.
Gender
Age at first presentation
Clinical manifestation
Biochemical examination, (maximal value)
Abdominal enhanced, CT scan
MRCP
Pathological features1
Pathological score
CK7
IHC5
Therapy
Outcome on 2024
1M24Haematemesis, Hematochezia, CholelithiasisTB 175, ALT 512, ALP 883, GGT 713, TBA 54Liver cirrhosis, Megalosplenia, ascitesCholecystitis, Cholelithiasis, CholedocholithiasisDuctopenia, cholestasis, hepatic fibrosisG1S4(+)NormalUDCA, transmetil, glycyrrheinDied
2M21Scleral icterus, Hepatic dysfunctionTB 29, ALT 159, ALP 346, GGT 1016, TBA 59Cholecystitis, splenomegalyIntrahepatic bile duct dilatationBile duct hyperplasiaG2S2(-)NormalUDCA, transmetil, Fenofibrate, glycyrrheinAlive
3M18Hepatic dysfunction, Pruritus, CholestasisTB 26, ALT 117, ALP 163, GGT 321, TBA 48CholangiectasisCholangiectasisBridging fibrosis, DuctopeniaG1S3(+)DecreaseUDCA, transmetil, glycyrrheinAlive
4M31Hepatic dysfunction, abdominal distention, jaundiceTB 7, ALT 80, ALP 139, GGT 309Hepatic cyst, splenomegaly/////UDCA, transmetil, glycyrrheinAlive
5F38Hepatic dysfunction, abdominal distention, edemaTB 72, ALT 52, ALP 528, GGT 233, TBA 257Splenectomy, Esophageal and gastric varices, liver cirrhosisMild dilation of bile ductDuctopenia, portal inflammationG2S4(+)DecreaseUDCA, Transmetil, glycyrrheinAlive